Axsome Therapeutics announced that the U.S. Food and Drug Administration, FDA, has acknowledged the resubmission of the Company’s New Drug Application, NDA, for AXS-07 for the acute treatment of migraine. The FDA designated the resubmission as a Class 2 resubmission and set a Prescription Drug User Fee Act, PDUFA, action goal date of January 31, 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics initiated with an Overweight at Wells Fargo
- Axsome Therapeutics to Participate in Investor Conferences in September
- Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
- Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
- Biotech Alert: Searches spiking for these stocks today
Questions or Comments about the article? Write to editor@tipranks.com